How Long Can You Stay on HRT? Duration, Monitoring, and Reassessment

One of the most common questions patients ask after starting hormone replacement therapy is deceptively simple:

How long can I stay on HRT?

There is no single number of months or years that is appropriate for everyone.

Some patients use hormone therapy temporarily while symptoms are most disruptive. Others may appropriately continue treatment for many years. In certain situations, hormone replacement may remain beneficial long term as long as the reason for treatment remains present, the patient continues to benefit, and treatment is regularly reassessed for safety.

For menopausal hormone therapy, current guidance does not require women to automatically stop treatment when they reach a particular age such as 60 or 65. Instead, treatment should be individualized and periodically reevaluated. The American College of Obstetricians and Gynecologists (ACOG) recommends discussing whether to continue hormone therapy each year based on symptoms, benefits, and risks. The Menopause Society similarly states that there is no general rule requiring hormone therapy to be stopped solely because a woman reaches age 65.

The same general principle applies to testosterone replacement therapy (TRT) in appropriately diagnosed men: treatment is not necessarily prescribed as a short course. Continued therapy depends on whether there remains a medical indication, symptoms improve, laboratory values remain appropriate, and adverse effects are adequately monitored.

The important question, therefore, is usually not “How many years have you been on HRT?”

It is:

“Does HRT still provide more benefit than risk for you now?”

HRT Does Not Have a Universal Expiration Date

Hormone replacement therapy is not like an antibiotic that is routinely prescribed for a predefined number of days.

Treatment duration depends on why hormone therapy was started in the first place.

For women, systemic hormone therapy may be prescribed to address symptoms associated with perimenopause or menopause, including hot flashes, night sweats, sleep disruption, and other bothersome menopausal symptoms. Hormone therapy may also help prevent bone loss in appropriately selected patients.

For men with appropriately diagnosed hypogonadism, testosterone replacement may be prescribed when compatible symptoms occur together with consistently low testosterone levels. Treatment may continue as long as the underlying indication remains and therapy continues to provide meaningful benefit without unacceptable risk.

You can learn more about the fundamentals of treatment in What Is Hormone Replacement Therapy? and our complete Hormone Replacement Therapy guide.

How Long Can Women Stay on HRT for Menopause?

There is no rule stating that all women must stop menopausal hormone therapy after five years, at age 60, or at age 65.

Earlier approaches to menopause treatment sometimes emphasized strict duration limits. Contemporary guidance places considerably more emphasis on individualized risk assessment.

ACOG recommends that a woman taking hormone therapy discuss continuation with her clinician every year. Some women may require longer treatment because menopausal symptoms can persist for years.

The Menopause Society likewise states that there is no general rule requiring treatment to stop based on age alone. Continuing hormone therapy beyond age 65 can be reasonable for appropriately selected women with persistent symptoms when counseling and regular assessment of benefits and risks are performed. Route, dose, and formulation become increasingly important as patients age.

This means that a woman who feels well on HRT does not necessarily need to stop treatment simply because she has had a birthday or reached an arbitrary treatment anniversary.

However, continued treatment should not mean unchanged treatment without reassessment.

As a patient ages, cardiovascular health, breast health, bone health, medications, family history, blood pressure, metabolic health, and other medical considerations can change. The treatment that was appropriate at age 52 may need to be modified at age 62 even if hormone therapy itself remains appropriate.

Is Five Years the Maximum for Menopausal HRT?

No.

Five years is sometimes mentioned because duration of exposure can influence certain hormone-related risks, particularly depending on whether estrogen is used alone or combined with a progestogen. The overall risk profile also depends on a woman's age, medical history, timing of treatment, dose, route of administration, and the specific hormonal regimen being used.

Therefore, reaching five years of therapy should generally prompt reassessment rather than automatic discontinuation.

A physician may determine that continuing the current treatment remains reasonable, that a lower dose is appropriate, that the route of administration should change, or that discontinuation should be considered.

The goal is not to keep someone on the same prescription indefinitely without question. The goal is to repeatedly determine whether the treatment still makes sense.

For a broader discussion of these considerations, see The Benefits and Risks of HRT.

Do You Have to Stop HRT at Age 60 or 65?

Not automatically.

Age is an important component of risk assessment, but it is not the only consideration.

The Menopause Society specifically notes that there is no general rule requiring women to discontinue menopausal hormone therapy because they have reached age 65. For healthy women who continue to experience significant symptoms, continued treatment may be considered with appropriate counseling and regular assessment.

There is also an important distinction between continuing therapy that was started earlier and starting systemic hormone therapy for the first time much later in life.

Starting systemic menopausal hormone therapy at an older age or many years after menopause may have a different benefit-risk profile than continuing therapy that was initiated earlier. This is one reason that decisions about HRT should consider not only a patient's current age but also when menopause occurred, when treatment began, medical history, and current risk factors.

In other words, “Is 65 too old for HRT?” is usually not enough information to make a medical decision.

What About Vaginal Estrogen?

Local vaginal estrogen deserves separate consideration from systemic hormone therapy.

Low-dose vaginal estrogen is primarily used for genitourinary syndrome of menopause, which may include vaginal dryness, irritation, painful intercourse, and certain urinary symptoms.

Because low-dose vaginal estrogen produces much lower systemic exposure than systemic estrogen therapy, its risk profile is different. The Menopause Society describes systemic absorption with low-dose vaginal estrogen as minimal and notes substantially lower risks compared with systemic hormone therapy.

In November 2025, the FDA removed the class-wide boxed warning from low-dose vaginal estrogen products used for genitourinary symptoms of menopause, a change supported by The Menopause Society.

For patients who only have vaginal or urinary menopausal symptoms, treatment decisions may therefore look very different from decisions about systemic estrogen used for hot flashes and night sweats.

How Long Can Men Stay on Testosterone Replacement Therapy?

Testosterone replacement therapy is frequently a long-term treatment when a man has confirmed hypogonadism and continues to benefit from therapy.

Unlike medications intended to permanently correct an underlying condition, testosterone replacement generally supplies testosterone while treatment is being used. Discontinuing therapy may therefore allow testosterone concentrations and related symptoms to return toward their untreated state.

The Endocrine Society recommends testosterone therapy for appropriately diagnosed hypogonadal men and recommends ongoing evaluation after treatment begins to assess response, adverse effects, and adherence.

There is not a predefined maximum number of years that every man can remain on TRT.

Instead, a physician periodically asks whether the original diagnosis remains appropriate, whether treatment is improving clinically meaningful symptoms, whether testosterone levels remain in the intended range, and whether treatment is creating new safety concerns.

Men considering therapy can read Testosterone Replacement Therapy and hormone treatment information for more information about how individualized treatment is approached.

Why Monitoring Matters More the Longer You Take HRT

Long-term hormone therapy should be an actively managed treatment—not a prescription that is automatically renewed year after year without review.

Monitoring allows the physician to answer several important questions:

• Is the treatment still helping?

• Are the original symptoms still present?

• Has the patient's overall health changed?

• Is the current dose still appropriate?

• Are laboratory values within acceptable ranges?

• Have new medications or medical conditions changed the risk-benefit calculation?

• Would another formulation or route provide a better safety profile?

• Is there still a clear reason to continue treatment?

The exact monitoring strategy differs between menopausal hormone therapy and testosterone therapy and should be individualized.

Monitoring Women Receiving Menopausal Hormone Therapy

Follow-up for menopausal HRT should include more than simply measuring hormone levels.

Menopause treatment is generally guided by symptoms, health history, clinical response, medication tolerance, and relevant risk factors. Routine hormone testing is not required simply to prove that a woman is in perimenopause when the clinical picture is otherwise clear. ACOG notes that perimenopause can often be identified from age, symptoms, and menstrual changes without hormone testing.

Depending on the patient, follow-up may include assessment of blood pressure, cardiovascular risk factors, breast health, abnormal vaginal bleeding, bone health, medication changes, family history, and whether menopausal symptoms continue to justify systemic therapy.

If unexpected postmenopausal bleeding occurs, it should not simply be attributed to HRT without appropriate evaluation.

Treatment may also need to be reconsidered if a patient develops a new medical condition that substantially changes the risk-benefit balance.

Monitoring Men Receiving Testosterone Therapy

Laboratory monitoring plays a more direct role in testosterone replacement therapy.

The diagnosis of male hypogonadism generally requires compatible symptoms together with unequivocally and consistently low testosterone concentrations. Once treatment begins, follow-up should evaluate clinical response and potential adverse effects.

Depending on the individual patient, monitoring may include testosterone levels, complete blood count and hematocrit, blood pressure, prostate-related evaluation when clinically appropriate, symptoms, sexual function, fertility considerations, sleep apnea symptoms, and other relevant health markers.

The FDA updated testosterone labeling in 2025 after reviewing cardiovascular safety data from the TRAVERSE trial and ambulatory blood-pressure studies. The agency removed prior boxed-warning language regarding increased adverse cardiovascular outcomes but added or strengthened warnings regarding increased blood pressure across testosterone products.

This is an example of why long-term TRT requires periodic medical supervision even when a patient feels well.

For a deeper explanation of testing, see Hormone Testing: Blood, Saliva & Urine Tests.

When Should HRT Be Reassessed?

HRT should be reassessed routinely rather than only when something goes wrong.

For menopausal hormone therapy, ACOG recommends discussing continuation every year.

Additional reassessment may be appropriate when symptoms change, a new medical diagnosis occurs, medications change, abnormal bleeding develops, cardiovascular or cancer-related risk factors change, the patient wishes to change formulations, or side effects appear.

TRT should likewise be reviewed after treatment begins and periodically thereafter to confirm treatment response and evaluate potential adverse effects.

A reassessment does not necessarily mean stopping treatment.

Sometimes the best decision is to continue exactly as before. In other cases, the dose may be lowered, the route changed, another medication added or removed, or therapy discontinued.

Reasons a Physician Might Adjust or Stop HRT

Several circumstances may cause the risk-benefit balance to change.

For example, treatment may require reconsideration if a patient develops a new hormone-sensitive cancer, thromboembolic disease, significant cardiovascular disease, unexplained bleeding, problematic adverse effects, uncontrolled blood pressure, substantial changes in laboratory values, or another condition that changes the safety of the current regimen.

The considerations differ considerably between estrogen-based menopausal therapy and testosterone replacement therapy.

This is why treatment should be evaluated individually rather than applying the same stopping rule to every patient.

Patients who are still deciding whether treatment is appropriate can also review Am I a Candidate for Hormone Replacement Therapy?.

What If Your Symptoms Are Completely Controlled?

Feeling better does not necessarily mean treatment is no longer needed.

In some cases, symptoms are controlled because the treatment is working.

A physician may occasionally recommend a dose reduction or trial off therapy to determine whether symptoms remain bothersome without treatment. For other patients, particularly those with persistent symptoms or another ongoing indication for hormone replacement, continuation may be reasonable.

The decision should take into account both symptom control and the patient's evolving health risks.

Can Menopause Symptoms Come Back After Stopping HRT?

Yes.

Hot flashes and other menopausal symptoms can recur after systemic hormone therapy is discontinued. The Menopause Society notes that there is no universally correct time to stop hormone therapy and that hot flashes may or may not return following discontinuation.

The possibility that symptoms may return is another reason stopping therapy should be a shared decision rather than an arbitrary requirement based only on treatment duration.

Some patients may ultimately remain off therapy. Others may decide with their physician that continued treatment provides a better balance of quality-of-life benefits and medical risks.

What About Early Menopause or Premature Ovarian Insufficiency?

The duration question is different for women who experience ovarian hormone loss substantially earlier than the typical age of natural menopause.

In premature ovarian insufficiency, hormone replacement has purposes beyond simply controlling hot flashes. Estrogen deficiency at a young age can affect bone, cardiovascular, sexual, and overall health.

ACOG notes that hormonal therapy in women with primary ovarian insufficiency is intended to replace hormones that the ovaries would ordinarily have been producing before the usual age of menopause.

As a result, treatment decisions in a 35-year-old with premature ovarian insufficiency should not be approached the same way as decisions regarding initiation of systemic HRT in a woman decades beyond natural menopause.

The Dose and Route May Change Even If HRT Continues

Long-term HRT does not necessarily mean remaining on the exact same formulation forever.

As symptoms and health risks evolve, a physician may modify the dose, medication, frequency, or route of administration.

For example, The Menopause Society emphasizes that dose and route become increasingly important considerations when systemic menopausal hormone therapy is continued in older women.

TRT formulations also differ in absorption patterns, dosing schedules, convenience, adverse effects, and laboratory responses.

This is one reason hormone therapy should be personalized rather than viewed as a standardized protocol.

Patients preparing to begin treatment can review A Patient's Guide to Starting Hormone Replacement Therapy.

Can You Stay on HRT for 10 Years?

Potentially, yes.

Ten years of treatment is not automatically too long.

Some women appropriately use menopausal hormone therapy for a decade or longer, while some men with confirmed testosterone deficiency remain on testosterone replacement for many years.

What matters is whether there continues to be an appropriate indication and whether ongoing reassessment shows that the expected benefits continue to outweigh potential risks.

Treatment duration alone cannot answer that question.

Can You Stay on HRT for Life?

For some patients, long-term or potentially lifelong hormone replacement may be medically appropriate.

For others, the indication for treatment eventually disappears or the risk-benefit balance changes.

Therefore, “lifelong HRT” should not mean deciding at the beginning of treatment that it will never be stopped.

A better approach is:

Continue treatment for as long as there is an appropriate indication, meaningful benefit, and acceptable safety profile—and reassess periodically.

The Bottom Line: How Long Can You Stay on HRT?

There is no universal maximum duration for hormone replacement therapy.

For women using systemic menopausal hormone therapy, neither five years of treatment nor reaching age 60 or 65 automatically means that treatment must stop. Current recommendations emphasize individualized decision-making and regular reassessment rather than mandatory age-based discontinuation.

For men receiving testosterone replacement therapy, treatment may also continue long term when hypogonadism has been appropriately diagnosed, meaningful benefits continue, laboratory and clinical monitoring remain acceptable, and treatment risks are periodically reviewed.

The safest approach to long-term hormone treatment is therefore not simply to ask how long you have been taking HRT, but to regularly evaluate:

Why are you taking it? Is it still helping? Has your health changed? Is your current regimen still the safest and most appropriate option?

Those questions should guide the decision to continue, modify, or discontinue treatment.

If you are considering hormone therapy or would like your current regimen reassessed, learn more about personalized Hormone Replacement Therapy in Arizona or explore the Ask Dr. Hu Hormone Replacement Therapy resources.

Evidence and Medical Review

This article is intended to provide evidence-informed patient education and reflects principles from major medical organizations involved in menopause and hormone care.

Current guidance referenced in preparing this article includes the American College of Obstetricians and Gynecologists' guidance on hormone therapy for menopause, The Menopause Society's hormone therapy resources, the Endocrine Society's Clinical Practice Guideline on testosterone therapy, and current U.S. Food and Drug Administration information regarding testosterone therapy.

Medical recommendations regarding HRT should always be individualized. Hormone therapy may not be appropriate for every patient, and decisions regarding initiation, continuation, dosage, route, and monitoring should be made with a qualified healthcare professional familiar with the patient's complete medical history.

About the Author

YiQiu Hu, NMD, is an Arizona-licensed naturopathic physician and medical director who provides personalized medical care to patients throughout Arizona. His clinical work includes preventive medicine, hormone replacement therapy, medical weight management, laboratory interpretation, and individualized health optimization.

Through Ask Dr. Hu, Dr. Hu provides physician-guided education and personalized care designed to help patients better understand their treatment options and make informed decisions about their health.

Learn more about Hormone Replacement Therapy at Ask Dr. Hu or explore additional physician-written health resources.

This article is for educational purposes and does not replace individualized medical evaluation, diagnosis, or treatment.